Shares of Tempus AI ( TEM 17.39%) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after ...

Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. The company's ...

BTIG analyst Mark Massaro has initiated coverage on Tempus AI (TEM), with a Buy rating and a price target of $60, implying 48 ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $63.78, ...

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report ...

Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and ...

Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors.

Tempus AI reports 30.4% YoY revenue growth in FY2024, driven by genomics and data services. Discover key metrics and ...

Tempus AI Inc (NASDAQ:TEM) shares closed up 14.5% following the announcement of expanded strategic partnerships with ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...